Companies-in-Development

Accelerating the development of new medical technologies

The companies currently hosted within Fogarty Innovation span a wide range of sectors and technologies. However they are all united by a common goal—improving patient care.

Companies-in-Residence

Boomerang Medical

Autoimmune diseases are the third most common category of disease in the U.S. after cancer and heart disease. According to the National Institutes of Health, autoimmune diseases affect up to 27 million people in the U.S. alone. Boomerang Medical is a bioelectronic medicine company developing technology to advance the treatment of autoimmune diseases by harnessing the body’s own “peripheral wiring” in order to manage inflammation and immune response.  Boomerang Medical is backed by Arboretum Ventures.  

Eclipse Regenesis

Current chronic therapies for short bowel syndrome (SBS), a malabsorption disorder caused by the lack of a functional small intestine, include expensive medication and intestinal surgery. These approaches have low success rates and a staggering average 5-year cost of care of $1.6 million per patient. Eclipse Regenesis is developing the first restorative therapy for pediatric and adult SBS patients, which harnesses the body’s own tissue regenerative capabilities to produce new, fully functional intestine.

 

Enspectra Health

The Enspectra Health imaging technology is being developed to address numerous clinical needs. The first application of this platform technology is skin health. The company’s VIO™ System is a hand-held technology that digitizes cell images non-invasively and in real-time. VIO combines novel multiphoton laser scanning with reflectance confocal microscopy to instantly generate high resolution digital images of live cells without the need for an incision.

G-Tech Medical

Up to 60 million individuals in the U.S. suffer from debilitating gastrointestinal disorders. G-Tech Medical is developing a wearable technology aimed at improving outcomes and reducing costs by non-invasively monitoring gastrointestinal tract activity.

iDentical

One hundred seventy-eight million adults in the United States are missing at least one tooth, and a surprising 40 million are missing all their teeth. Currently, dental implants are the top choice of treatment, yet less than two percent of those impacted by tooth loss are able to reap the benefits due to limited accessibility, high cost, high risk and long treatment time. iDentical is leveraging the latest 3D technology to offer a safer, faster and more affordable solution through its drill-free, non-invasive dental implants.

Materna Medical

Approximately 50 percent of all women in the U.S. will suffer symptoms of a pelvic floor disorder resulting from childbirth by the time they turn 55, and over 20 million suffer from pelvic pain. Materna has developed an obstetrics and gynecology (OB-GYN) platform of medical devices: the first, Prep, is aimed at preventing maternal pelvic injuries during childbirth and shortening delivery time; the second, Milli, is helping treat pelvic pain and dyspareunia.